CervoMed
CRVO
10 hedge funds and large institutions have $2.51M invested in CervoMed in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 2 closing their positions.
389% more capital invested
Capital invested by funds: $513K → $2.51M (+$1.99M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Swift Run Capital Management
Charlottesville,
Virginia
|
+$1.98M |
| 2 |
WTC
WhitTier Trust Company
Reno,
Nevada
|
+$367K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$238K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$110K |
| 5 |
BlackRock
New York
|
+$45.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$61K |
| 2 |
Morgan Stanley
New York
|
-$35.4K |
CRVO Hedge Fund Activity: Q2 2017 in Review
10 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CervoMed (CRVO) for Q2 2017, worth a combined $2.51M — up 389% from $513K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CRVO positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Swift Run Capital Management, opening a new position worth an estimated $1.98M. The largest seller was Goldman Sachs, exiting entirely with an estimated $61K sold.
- 10 institutional investors held CervoMed (CRVO) as of Q2 2017, up from 8 in Q1 2017.
- Funds reported $2.51M of CervoMed stock for Q2 2017, up 389% quarter-over-quarter.
- 4 funds opened new CervoMed positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest CervoMed buyer in Q2 2017 was Swift Run Capital Management, an estimated $1.98M added.
- The largest CervoMed seller in Q2 2017 was Goldman Sachs, an estimated $61K sold.
Based on aggregated 13F filings for Q2 2017.